Chris Bulman Inc Bio N Tech Se Call Options Transaction History
Chris Bulman Inc
- $147 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BNTX
# of Institutions
356Shares Held
38.3MCall Options Held
2.45MPut Options Held
2.29M-
Baillie Gifford & CO8.31MShares$899 Million0.75% of portfolio
-
Primecap Management CO Pasadena, CA4.52MShares$489 Million0.4% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.36MShares$472 Million2.05% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$205 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$196 Million0.88% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $26.3B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...